SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE.X is trending as the community rallies around the meme-based token, expressing bullish sentiment and encouraging others to join. The community is actively promoting the token and celebrating its trending status, with some highlighting support from notable investors. Discussions revolve around community strength and the potential for significant growth.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amidst mixed sentiment, with some community members questioning the burn mechanism and others anticipating a potential bull run. There's also discussion around alternative meme coins, like $PUPU.X and $SHITCOIN.X, potentially drawing attention away from SHIB.X.

Clown Pepe, also known as Honk, its original name pepoclown, is a depiction of Pepe the Frog wearing a rainbow wig and red clown nose.  $HONK, the meme coin with 0 taxes, draws its inspiration from Clown Pepe, also known as Honk Honk or Honkler. This whimsical character, originally named pepoclown, depicts Pepe the Frog donning a rainbow wig and a red clown nose. Honkler is often associated with corny or cringeworthy jokes and the emojis, symbolizing the phrase "Clown World." Embracing the chaotic and absurd nature of meme culture, $HONK aims to bring humor, memes and vibes to the space.

Pepoclown

$HONK.X is trending as the mascot of "clown world," with the community drawing comparisons to $PEPE.X and other 4chan-inspired memes. Some community members believe that $HONK.X is undervalued and poised for significant growth, touting its strong community and distinctive lore.

Pupu is a community-driven meme project centered around the character “Pupu the Frog,” who represents lighthearted fun and adventure within the crypto space. The project aims to build a digital ecosystem where holders can engage with the narrative of Pupu through memes, social interactions, and community activities. At its core, the project highlights creativity, entertainment, and community participation as primary utilities, while maintaining a transparent and decentralized structure that evolves through user engagement.

Pupu

$PUPU.X is trending as social media buzz compares it to PEPE, with community members suggesting it could be the next big meme coin. The crypto, built on Solana, is gaining attention as traders look for the next potential 'moonshot' opportunity.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending due to a recent AI hosting agreement with Fluidstack, backstopped by Google, which provides significant contracted revenue and validation for its shift towards high-performance computing; however, the announcement coincided with an $800 million convertible note offering, sparking dilution concerns among investors and leading to community discussion around market appetite and strategic missteps. Despite the drop, some view this as a buying opportunity, citing Google's involvement and the potential for future growth in the AI data center space.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

NEGG is trending due to high short interest and borrow rates, sparking community discussion about a potential short squeeze. Traders are closely monitoring Fintel data and insider buying activity, particularly by Galkin, for further signals. The stock's volatile price action and tight float continue to fuel speculation and trading strategies among retail investors.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals is trending following FDA approval of PALSONIFY for acromegaly treatment, sparking discussions about the drug's market potential and potential buyout scenarios. Community members are analyzing the implications of the approval, including potential revenue, market competition, and the possibility of a short squeeze. Trading halts and overnight order rejections are adding to the buzz as investors anticipate significant price movement.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as community members discuss its potential exemption from pharmaceutical tariffs due to its U.S. manufacturing plants and expansion, a perceived advantage over competitors. Bullish sentiment is fueled by upcoming obesity pill approvals and expectations for exceptional business growth, though some express concern about layoffs and competitive pressures from other weight loss drugs. Many see the recent dip as a buying opportunity, while others speculate on potential price targets and future growth.

CarMax, Inc. is a holding company, which engages in the retail of used vehicles and wholesale of vehicle auction operators. It operates through the CarMax Sales Operations and CarMax Auto Finance (CAF) segments. The CarMax Sales Operations segment consists of all aspects of its auto merchandising and service operations. The CAF segment pertains to its finance operation, which offers vehicle financing services to customers buying retail vehicles. The company was founded by Richard L. Sharp and William Austin Ligon in 1993 and is headquartered in Richmond, VA.

Carmax Inc

CarMax ($KMX) is trending due to a significant stock drop following disappointing Q2 results, which revealed slumping car sales and increased loan loss provisions. The community is discussing whether this signals broader issues within the used car market and comparing KMX's business model to competitors like Carvana. Some investors view the dip as a buying opportunity, citing the company's profitability and aggressive buyback program, while others are concerned about debt and the potential impact of AI on car ownership.

Eason Technology Ltd. engages in the provision of loan facilities to micro, small and medium size enterprises, and sole proprietors. It also offers microfinance lending services. The company was founded by Qi Ming Xu and Kang Kai Zeng on June 24, 2010 and is headquartered in Wuhan, China.

Eason Technology Ltd. - ADR

Eason Technology Ltd ADR

DXF is trending due to increased interest in low float Chinese stocks, with many traders anticipating a potential breakout and comparing it to previous runners. Community members are closely watching for news or a PR, particularly regarding compliance filings or a crypto-related announcement, which they believe could trigger a significant price surge. Some traders are noting the stock's history of volatility and range-bound trading, while others are expressing concerns about potential manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates

Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of -13.89% and -59.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Prime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy?

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

3 Genomics Stocks Worth Adding to Your Portfolio in 2025

CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech

Prime Medicine stock soars amid gene editing sector momentum

Investing.com --  Prime Medicine  (NASDAQ:PRME) stock rose 32%, extending recent gains following Eli Lilly’s (NYSE:LLY) acquisition deal for  Verve Therapeutics  (NASDAQ:VERV) last month. 

Retail chatter for Prime Medicine spiked Monday following Citi's downgrade to 'Neutral' from 'Buy,' with the price target slashed to $1.50 from $10.&nbsp;According to Citi's research note, the shares were trading near cash, reflecting investor uncertainty over the company's path to value inflection.Citi said that Prime Medicine's cash reserves will sustain operations only until mid-2026 despite recent efforts to cut costs and restructure operations.However, management expects initial clinical data will become available for Wilson's Disease and Alpha-1 Antitrypsin Deficiency (AATD) in 2027.Prime Medicine’s shares closed at $1.29 on Friday, up 4.88% or $0.06 for the day.The company said it would restructure by making its Chronic Granulomatous Disease (CGD) programs a lower priority while cutting its workforce by about 25% to concentrate on the liver disease franchise and externally funded programs.The firm maintains progress in its live studies that target two significant genetic liver conditions: Wilson's Disease and Alpha-1 Antitrypsin Deficiency (AATD).It plans to file an investigational new drug (IND) application in the first half of 2026 and mid-2026, respectively. Initial clinical data for these programs are expected in 2027.Prime Medicine also maintains its cystic fibrosis program, which is supported by the Cystic Fibrosis Foundation, and collaborates with Bristol Myers Squibb to develop Prime Edited CAR-T products in hematology, immunology, and oncology.On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.One user noted insider buying and a technical double bottom pattern, suggesting the stock could either become a complete write-off or achieve “legendary” success.<stembedurl>https://stocktwits.com/sogenerous/message/615704325</stembedurl>Meanwhile, another user highlighted the company's gene-editing technology and its long-term potential despite the lengthy clinical timelines.<stembedurl>https://stocktwits.com/Shesellsseashells/message/615286716</stembedurl>The stock has declined 57% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic picture shows a hand holidng a capsule on 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Citi Downgrade Sparks Retail Chatter On Prime Medicine Amid Cash Runway Uncertainty

The biotech firm announced a restructuring to focus on its liver disease programs while cutting costs and workforce amid ongoing development challenges.

Equity

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More

Shares of biotechnology company Prime Medicine, Inc. (PRME) fell 18% on Monday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.primemedicine.com/news-releases/news-release-details/prime-medicine-announces-strategic-restructuring-focus">announced</a> a strategic restructuring, including layoffs and the resignation of its CEO in a bid to reduce cash burn.Prime Medicine announced that Keith Gottesdiener will step down as CEO and a member of the company’s board of directors, effective immediately.Allan Reine, Prime Medicine’s Chief Financial Officer (CFO), will now succeed Gottesdiener.The company also announced the deprioritization of its programs aimed at the genetic disorder Chronic Granulomatous Disease (CGD), instead focusing its efforts on the development of programs for genetic liver diseases, Wilson’s Disease, and Alpha-1 Antitrypsin Deficiency (AATD).The company expects to file an investigational new drug (IND) and/or clinical trial application (CTA) for its Wilson’s Disease program in the first half of 2026 and its AATD program in mid-2026. Initial clinical data from both programs is expected the following year.For its CGD program, PM359, the company said it is exploring options for continued clinical development outside the firm.However, the company expressed confidence in the program and believes it has the potential to transform the treatment of the disorder.Prime Medicine also said it is reducing its organizational headcount by approximately 25%.The company believes the multiple initiatives will reduce anticipated cash needs by almost half through 2027.Prime Medicine expects that its cash, cash equivalents, and investments as of March 31, 2025, will be sufficient to fund its operations and capital expenditure requirements into the first half of 2026.On Stocktwits, retail sentiment around PRME rose within the ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_19_at_12_06_01_PM_png_ee21a5e357.webp" alt="PRME's Sentiment Meter and Message Volume as of 12:05 p.m. ET on May 19, 2025 | Source: Stocktwits" width="628" height="65"><figcaption>PRME's Sentiment Meter and Message Volume as of 12:05 p.m. ET on May 19, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/PRME">PRME stock</a> is down by about 57% this year and 83% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/protagenic-therapeutics-merges-with-phytanix-bio/ch0cuACRb8E">Protagenic Therapeutics Merges With Phytanix Bio In All-Stock Deal: Retail Turns Extremely Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Prime Medicine Announces Layoffs, CEO Transition: Retail Gets More Bullish

The company said Keith Gottesdiener will step down as the chief executive, while CFO Allan Reine will succeed him.

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 30, 2025 NEW YORK...

Analyst: Sell ‘Magnificent 7’ Stocks and Buy These 3 Dividend Stocks Instead

Analysts at Miramar Capital are advising investors to sell “Magnificent 7” and instead invest in lower-valuation, dividend-paying healthcare stocks.

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Prime Medicine Inc

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

PRME
Prime Medicine Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PRME News

PRME Prime Medicine Inc